These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36314246)

  • 1. Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.
    He F; Chen W; Xu W; Liu D; Xiao Z; Tang Y; Lin Z; Liao Y; Bin J; Chen G; Chen Y
    Diabetes Obes Metab; 2023 Mar; 25(3):664-674. PubMed ID: 36314246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.
    van Eyk HJ; Paiman EHM; Bizino MB; de Heer P; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Smit JWA; Lamb HJ; Rensen PCN; Jazet IM
    Cardiovasc Diabetol; 2019 Jul; 18(1):87. PubMed ID: 31288820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
    Neeland IJ; Marso SP; Ayers CR; Lewis B; Oslica R; Francis W; Rodder S; Pandey A; Joshi PH
    Lancet Diabetes Endocrinol; 2021 Sep; 9(9):595-605. PubMed ID: 34358471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    Wang X; Wu N; Sun C; Jin D; Lu H
    Diabetol Metab Syndr; 2023 May; 15(1):113. PubMed ID: 37254186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
    Bizino MB; Jazet IM; de Heer P; van Eyk HJ; Dekkers IA; Rensen PCN; Paiman EHM; Lamb HJ; Smit JW
    Diabetologia; 2020 Jan; 63(1):65-74. PubMed ID: 31690988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.
    Du Q; Wang YJ; Yang S; Zhao YY; Han P
    Adv Ther; 2014 Nov; 31(11):1182-95. PubMed ID: 25388240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    Liao C; Liang X; Zhang X; Li Y
    PLoS One; 2023; 18(8):e0289616. PubMed ID: 37616255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
    J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.
    Schmidt S; Frandsen CS; Dejgaard TF; Vistisen D; Halldórsson T; Olsen SF; Jensen JB; Madsbad S; Andersen HU; Nørgaard K
    Diabetes Obes Metab; 2022 Feb; 24(2):212-220. PubMed ID: 34595827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.
    Kajiwara M; Tanaka A; Kawasaki T; Nakao K; Sakamoto T; Toyoda S; Inoue T; Koga N; Node K
    J Cardiol; 2017 Mar; 69(3):511-517. PubMed ID: 27894787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Xu YY; Wang X; She YQ; Liu J; Zhang Q
    Endocr J; 2024 Jun; ():. PubMed ID: 38910131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study.
    Yu D; Zou M; Pan Q; Song Y; Li M; Zhang X; Zhou Y; Wang X; Guo L
    Front Endocrinol (Lausanne); 2022; 13():951570. PubMed ID: 36093105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.
    Ayers D; Kanters S; Goldgrub R; Hughes M; Kato R; Kragh N
    Curr Med Res Opin; 2017 Sep; 33(9):1653-1661. PubMed ID: 28635331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
    Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials.
    Wang L; Xin Q; Wang Y; Chen Z; Yuan R; Miao Y; Zhang G; Cong W
    Pharmacol Res; 2021 Sep; 171():105765. PubMed ID: 34252552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Kalogirou MS; Patoulias D; Haidich AB; Akriviadis E; Sinakos E
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101568. PubMed ID: 33309563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials.
    Zhao D; Liu H; Dong P
    Clin Exp Hypertens; 2020 Jul; 42(5):393-400. PubMed ID: 31610701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.